2020 Obsessive Compulsive Disorder (OCD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Obsessive Compulsive Disorder (OCD) pipeline report presents a comprehensive overview of the research and development of Obsessive Compulsive Disorder (OCD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, four drugs in Pre-clinical phase, one drug in Phase 1, one drugs in Phase 2 and one drug in Phase 3
As of February 2020, the Obsessive Compulsive Disorder (OCD) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Obsessive Compulsive Disorder (OCD) treatment. Diverse types of targeted therapies are being explored through clinical trials including CB1 and CB2 receptor agonist; Glutamate modulator; Metabotropic glutamate receptor 4 agonist; NMDA receptor antagonist; PDE7 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Obsessive Compulsive Disorder (OCD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Obsessive-Compulsive Disorder pipeline drugs profiled in the report include- ADX88178, NMDA Receptor for Obsessive Compulsive Disorder, rituximab, troriluzole (BHV-4157), CBIS-OCD-001, OMS527, PECS-101, SERx-480
As of February 2020, the Obsessive Compulsive Disorder (OCD) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Obsessive Compulsive Disorder (OCD) treatment. Diverse types of targeted therapies are being explored through clinical trials including CB1 and CB2 receptor agonist; Glutamate modulator; Metabotropic glutamate receptor 4 agonist; NMDA receptor antagonist; PDE7 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Obsessive Compulsive Disorder (OCD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Obsessive Compulsive Disorder (OCD) development
- Obsessive Compulsive Disorder (OCD) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Obsessive Compulsive Disorder (OCD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Obsessive Compulsive Disorder (OCD) pipeline candidates included
- Business overview and snapshot of all companies involved in Obsessive Compulsive Disorder (OCD) pipeline are included
- Latest market and pipeline developments are provided in the report
Obsessive-Compulsive Disorder pipeline drugs profiled in the report include- ADX88178, NMDA Receptor for Obsessive Compulsive Disorder, rituximab, troriluzole (BHV-4157), CBIS-OCD-001, OMS527, PECS-101, SERx-480
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Obsessive-Compulsive Disorder Condition
2.3 Obsessive-Compulsive Disorder Pipeline Snapshot, 2020
2.4 Companies investing in Obsessive-Compulsive Disorder pipeline therapeutics
2.5 Phase wise Obsessive-Compulsive Disorder Pipeline Candidates
2.6 Most Researched Mechanism of Action of Obsessive-Compulsive Disorder Pipeline Products
2.7 Route of Administration of Obsessive-Compulsive Disorder Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Amorsa Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Cannabis Science Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.7 Phytecs Overview, Contacts and ASD Pipeline Drugs
3.8 Seropeutics LLC Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ADX88178 Drug Details
4.1.1 ADX88178 Current Status
4.1.2 ADX88178 Drug Overview
4.1.3 ADX88178 Mechanism of Action
4.1.4 ADX88178 Licensing/Collaboration Companies
4.1.5 ADX88178 Clinical Trials
4.2 NMDA Receptor for Obsessive Compulsive Disorder Drug Details
4.2.1 NMDA Receptor for Obsessive Compulsive Disorder Current Status
4.2.2 NMDA Receptor for Obsessive Compulsive Disorder Drug Overview
4.2.3 NMDA Receptor for Obsessive Compulsive Disorder Mechanism of Action
4.2.4 NMDA Receptor for Obsessive Compulsive Disorder Licensing/Collaboration Companies
4.2.5 NMDA Receptor for Obsessive Compulsive Disorder Clinical Trials
4.3 rituximab Drug Details
4.3.1 rituximab Current Status
4.3.2 rituximab Drug Overview
4.3.3 rituximab Mechanism of Action
4.3.4 rituximab Licensing/Collaboration Companies
4.3.5 rituximab Clinical Trials
4.4 troriluzole (BHV-4157) Drug Details
4.4.1 troriluzole (BHV-4157) Current Status
4.4.2 troriluzole (BHV-4157) Drug Overview
4.4.3 troriluzole (BHV-4157) Mechanism of Action
4.4.4 troriluzole (BHV-4157) Licensing/Collaboration Companies
4.4.5 troriluzole (BHV-4157) Clinical Trials
4.5 CBIS-OCD-001 Drug Details
4.5.1 CBIS-OCD-001 Current Status
4.5.2 CBIS-OCD-001 Drug Overview
4.5.3 CBIS-OCD-001 Mechanism of Action
4.5.4 CBIS-OCD-001 Licensing/Collaboration Companies
4.5.5 CBIS-OCD-001 Clinical Trials
4.6 OMS527 Drug Details
4.6.1 OMS527 Current Status
4.6.2 OMS527 Drug Overview
4.6.3 OMS527 Mechanism of Action
4.6.4 OMS527 Licensing/Collaboration Companies
4.6.5 OMS527 Clinical Trials
4.7 PECS-101 Drug Details
4.7.1 PECS-101 Current Status
4.7.2 PECS-101 Drug Overview
4.7.3 PECS-101 Mechanism of Action
4.7.4 PECS-101 Licensing/Collaboration Companies
4.7.5 PECS-101 Clinical Trials
4.8 SERx-480 Drug Details
4.8.1 SERx-480 Current Status
4.8.2 SERx-480 Drug Overview
4.8.3 SERx-480 Mechanism of Action
4.8.4 SERx-480 Licensing/Collaboration Companies
4.8.5 SERx-480 Clinical Trials
5. LATEST OBSESSIVE-COMPULSIVE DISORDER PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Obsessive-Compulsive Disorder Condition
2.3 Obsessive-Compulsive Disorder Pipeline Snapshot, 2020
2.4 Companies investing in Obsessive-Compulsive Disorder pipeline therapeutics
2.5 Phase wise Obsessive-Compulsive Disorder Pipeline Candidates
2.6 Most Researched Mechanism of Action of Obsessive-Compulsive Disorder Pipeline Products
2.7 Route of Administration of Obsessive-Compulsive Disorder Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Amorsa Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Cannabis Science Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.7 Phytecs Overview, Contacts and ASD Pipeline Drugs
3.8 Seropeutics LLC Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ADX88178 Drug Details
4.1.1 ADX88178 Current Status
4.1.2 ADX88178 Drug Overview
4.1.3 ADX88178 Mechanism of Action
4.1.4 ADX88178 Licensing/Collaboration Companies
4.1.5 ADX88178 Clinical Trials
4.2 NMDA Receptor for Obsessive Compulsive Disorder Drug Details
4.2.1 NMDA Receptor for Obsessive Compulsive Disorder Current Status
4.2.2 NMDA Receptor for Obsessive Compulsive Disorder Drug Overview
4.2.3 NMDA Receptor for Obsessive Compulsive Disorder Mechanism of Action
4.2.4 NMDA Receptor for Obsessive Compulsive Disorder Licensing/Collaboration Companies
4.2.5 NMDA Receptor for Obsessive Compulsive Disorder Clinical Trials
4.3 rituximab Drug Details
4.3.1 rituximab Current Status
4.3.2 rituximab Drug Overview
4.3.3 rituximab Mechanism of Action
4.3.4 rituximab Licensing/Collaboration Companies
4.3.5 rituximab Clinical Trials
4.4 troriluzole (BHV-4157) Drug Details
4.4.1 troriluzole (BHV-4157) Current Status
4.4.2 troriluzole (BHV-4157) Drug Overview
4.4.3 troriluzole (BHV-4157) Mechanism of Action
4.4.4 troriluzole (BHV-4157) Licensing/Collaboration Companies
4.4.5 troriluzole (BHV-4157) Clinical Trials
4.5 CBIS-OCD-001 Drug Details
4.5.1 CBIS-OCD-001 Current Status
4.5.2 CBIS-OCD-001 Drug Overview
4.5.3 CBIS-OCD-001 Mechanism of Action
4.5.4 CBIS-OCD-001 Licensing/Collaboration Companies
4.5.5 CBIS-OCD-001 Clinical Trials
4.6 OMS527 Drug Details
4.6.1 OMS527 Current Status
4.6.2 OMS527 Drug Overview
4.6.3 OMS527 Mechanism of Action
4.6.4 OMS527 Licensing/Collaboration Companies
4.6.5 OMS527 Clinical Trials
4.7 PECS-101 Drug Details
4.7.1 PECS-101 Current Status
4.7.2 PECS-101 Drug Overview
4.7.3 PECS-101 Mechanism of Action
4.7.4 PECS-101 Licensing/Collaboration Companies
4.7.5 PECS-101 Clinical Trials
4.8 SERx-480 Drug Details
4.8.1 SERx-480 Current Status
4.8.2 SERx-480 Drug Overview
4.8.3 SERx-480 Mechanism of Action
4.8.4 SERx-480 Licensing/Collaboration Companies
4.8.5 SERx-480 Clinical Trials
5. LATEST OBSESSIVE-COMPULSIVE DISORDER PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
